NI
NIVF.US NewGenIvf Group Limited Class A Ordinary Shares
- Market cap
- USD 328K
- P/E
- -
- P/B
- 0.01x
- ROE
- -121,613.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is NIVF.US undervalued?
Graham numberThe Graham number of NewGenIvf Group Limited Class A Ordinary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NewGenIvf Group Limited Class A Ordinary Shares fundamental analysis
No fundamental analysis for NewGenIvf Group Limited Class A Ordinary Shares yet.
NewGenIvf Group Limited Class A Ordinary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NewGenIvf Group Limited Class A Ordinary Shares
NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freez…
Full company profileNewGenIvf Group Limited Class A Ordinary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NewGenIvf Group Limited Class A Ordinary Shares annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 4.12M | 5.94M | 5.14M | 5.43M | 4.73M | 7.70B |
| Gross Profit | 1.03M | 1.54M | 1.68M | 1.83M | 956K | 1.86B |
| Operating Income | 199K | 399K | -2.52M | -1.16M | -10.7M | -14.2B |
| EBITDA | 587K | 726K | -2.52M | 24.3K | 10.8M | -30.2B |
| Net Income | -533.00 | 459K | -691K | -525K | 9.88M | -32.1B |
| EPS | -0.07 | 63 | -0.13 | -32 | 605 | -1,967,027 |
| Balance Sheet | ||||||
| Total Assets | 1.41M | 2.90M | 21.3M | 3.58M | 32.7M | 36.4M |
| Total Liabilities | 2.33M | 2.80M | 5.72M | 5.06M | 6.74M | 10.7M |
| Shareholders' Equity | -776K | 563K | 15.6M | -1.05M | 26.6M | 26.4M |
| Cash & Short-term Investments | 28.8K | 27.6K | 42.2K | 458K | 759K | 1.02M |
| Total Debt | 926K | 452K | 1.62M | 3.03M | 4.86M | 1.58M |
| Cash Flow | ||||||
| Operating Cash Flow | 1.43M | -527K | -857K | -8.26M | -10.9M | - |
| Capital Expenditure | 16.6K | 94.5K | 69.8K | 53.0K | 5.75M | - |
| Free Cash Flow | 1.42M | -622K | -927K | -8.32M | -16.7M | - |
| Ratios | ||||||
| ROE | - | 81.5% | -4.4% | - | 37.1% | -121,613.7% |
| ROA | 0.0% | 15.8% | -3.2% | -14.7% | 30.2% | -88,210.5% |
| Net Profit Margin | 0.0% | 7.7% | -13.5% | -9.7% | 209.0% | -417.4% |
| Debt to Equity | - | 0.80x | 0.10x | - | 0.18x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
NewGenIvf Group Limited Class A Ordinary Shares dividends
NewGenIvf Group Limited Class A Ordinary Shares has not paid dividends in the last 5 fiscal years.
Last stock split: 1:8 on Oct 23, 2026.
Who owns NewGenIvf Group Limited Class A Ordinary Shares
- Insiders 3.16%
- Institutions 0.26%
- Public & others 96.58%
- Shares outstanding 1.59M
- Free float 35.6K
Top institutions holding NIVF.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| UBS Group AG | 60.3K | 0.22% | +30,026.00% | Jun 2026 |
| Tower Research Capital LLC | 10.0K | 0.04% | +566.67% | Jun 2026 |
| SBI Securities Co Ltd | 115.00 | 0.00% | +2,200.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
NewGenIvf Group Limited Class A Ordinary Shares company profile
- Company name
- NewGenIvf Group Limited Class A Ordinary Shares
- Ticker
- NIVF.US
- ISIN
- VGG0544E1051
- Exchange
- USA Stocks
- Listed since
- Apr 3, 2024
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 87
- Fiscal year end
- December
- Address
- PS Tower,36/39-36/40, Bangkok, Thailand, 10110
- Phone
- 66 2 116 9641
- Website
- nivf.global
About NewGenIvf Group Limited Class A Ordinary Shares
NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freezing. It also offers IVF treatment; surrogacy and ancillary caring services, and value-added services comprising nutrition guidance, psychological counselling, acupuncture, and translation interpreters to supplement the IVF treatment. The company provides its services through clinics. NewGenIvf Group Limited was founded in 2010 and is based in Bangkok, Thailand.
NewGenIvf Group Limited Class A Ordinary Shares management
3- Mr. Wing Fung SiuCo-Founder, Chairman & CEO · born 1956
- Ms. Hei Yue FongCo-Founder, Chief Marketing Officer & Director · born 1982
- Mr. Ho Fai ChungChief Financial Officer · born 1964